Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2008, Article ID 683505, 10 pages
http://dx.doi.org/10.1155/2008/683505
Research Article

Mouse Mammary Tumor Virus Promoter-Containing Retroviral Promoter Conversion Vectors for Gene-Directed Enzyme Prodrug Therapy are Functional in Vitro and in Vivo

1Austrianova Biotechnology GmbH, Veterinärplatz 1, A-1210 Vienna, Austria
2Children’s Cancer Research Institute, Kinderspitalgasse 6, A-1090 Vienna, Austria
3Research Institute of Virology and Biomedicine, University of Veterinary Medicine, Veterinärplatz 1, A-1210 Vienna, Austria
4Department of Pathobiology, University of Veterinary Medicine, Veterinärplatz 1, A-1210 Vienna, Austria
5Department of Pharmacology and Toxicology, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria

Received 1 October 2007; Accepted 14 December 2007

Academic Editor: Kanury V. S. Rao

Copyright © 2008 Reinhard Klein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. R. McKeown, C. Ward, and T. Robson, “Gene-directed enzyme prodrug therapy: a current assessment,” Current Opinion in Molecular Therapeutics, vol. 6, no. 4, pp. 421–435, 2004. View at Google Scholar
  2. N. E. Sladek, “Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines,” in Anticancer Drugs: Reactive Metabolism and Interactions, G. Powers, Ed., pp. 79–156, Pergamon Press, Oxford, UK, 1994. View at Google Scholar
  3. L. Clarke and D. J. Waxman, “Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation,” Cancer Research, vol. 49, no. 9, pp. 2344–2350, 1989. View at Google Scholar
  4. T. K. Chang, G. F. Weber, C. L. Crespi, and D. J. Waxman, “Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes,” Cancer Research, vol. 53, no. 23, pp. 5629–5637, 1993. View at Google Scholar
  5. L. Chen and D. J. Waxman, “Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy,” Cancer Research, vol. 55, no. 3, pp. 581–589, 1995. View at Google Scholar
  6. M. X. Wei, T. Tamiya, R. J. Rhee, X. O. Breakefield, and E. A. Chiocca, “Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm,” Clinical Cancer Research, vol. 1, no. 10, pp. 1171–1177, 1995. View at Google Scholar
  7. L. Hennighausen, “Mouse models for breast cancer,” Breast Cancer Research, vol. 2, no. 1, pp. 2–7, 2000. View at Publisher · View at Google Scholar
  8. T. A. Stewart, P. K. Pattengale, and P. Leder, “Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes,” Cell, vol. 38, no. 3, pp. 627–637, 1984. View at Publisher · View at Google Scholar
  9. S. R. Ross and D. Solter, “Glucocorticoid regulation of mouse mammary tumor virus sequences in transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 17, pp. 5880–5884, 1985. View at Publisher · View at Google Scholar
  10. K.-U. Wagner, R. J. Wall, L. St-Onge et al., “Cre-mediated gene deletion in the mammary gland,” Nucleic Acids Research, vol. 25, no. 21, pp. 4323–4330, 1997. View at Publisher · View at Google Scholar
  11. F. Ahmed, J. Wyckoff, E. Y. Lin et al., “GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice,” Cancer Research, vol. 62, no. 24, pp. 7166–7169, 2002. View at Google Scholar
  12. E. R. Andrechek, M. A. Laing, A. A. Girgis-Gabardo, P. M. Siegel, R. D. Cardiff, and W. J. Muller, “Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers,” Cancer Research, vol. 63, no. 16, pp. 4920–4926, 2003. View at Google Scholar
  13. B. Muñoz and F. F. Bolander Jr., “Prolactin regulation of mouse mammary tumor virus (MMTV) expression in normal mouse mammary epithelium,” Molecular and Cellular Endocrinology, vol. 62, no. 1, pp. 23–29, 1989. View at Publisher · View at Google Scholar
  14. J. Svec and J. Links, “Mouse mammary tumor virus production stimulated by hormones and polyamines in cells grown in semi-synthetic in vitro conditions,” International Journal of Cancer, vol. 19, no. 2, pp. 249–257, 1977. View at Publisher · View at Google Scholar
  15. J. Ham, A. Thomson, M. Needham, P. Webb, and M. Parker, “Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus,” Nucleic Acids Research, vol. 16, no. 12, pp. 5263–5276, 1988. View at Publisher · View at Google Scholar
  16. E. Weber, W. F. Anderson, and N. Kasahara, “Recent advances in retrovirus vector-mediated gene therapy: teaching an old vector new tricks,” Current Opinion in Molecular Therapeutics, vol. 3, no. 5, pp. 439–453, 2001. View at Google Scholar
  17. J. E. McCormack, W. Edwards, J. Sensintaffer et al., “Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector,” Molecular Therapy, vol. 3, no. 4, pp. 516–525, 2001. View at Publisher · View at Google Scholar
  18. B. Salmons and W. H. Gunzburg, “Targeting of retroviral vectors for gene therapy,” Human Gene Therapy, vol. 4, no. 2, pp. 129–141, 1993. View at Google Scholar
  19. R. M. Saller, S. Indraccolo, V. Coppola et al., “Encapsulated cells producing retroviral vectors for in vivo gene transfer,” Journal of Gene Medicine, vol. 4, no. 2, pp. 150–160, 2002. View at Publisher · View at Google Scholar
  20. O. Martinet, N. Schreyer, E. D. Reis, and J.-M. Joseph, “Encapsulation of packaging cell line results in succesful retroviral-mediated transfer of a suicide gene in vivo in an experimental model of glioblastoma,” European Journal of Surgical Oncology, vol. 29, no. 4, pp. 351–357, 2003. View at Publisher · View at Google Scholar
  21. A. Krupetsky, Z. Parveen, E. Marusich, A. Goodrich, and R. Dornburg, “Retroviral packaging cells encapsulated in theracyte immunoisolation devices enable long-term in vivo gene delivery,” Frontiers in Bioscience, vol. 8, pp. a94–a101, 2003. View at Publisher · View at Google Scholar
  22. M. Löhr, P. Müller, P. Karle et al., “Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450,” Gene Therapy, vol. 5, no. 8, pp. 1070–1078, 1998. View at Google Scholar
  23. T. Kammertoens, W. Gelbmann, P. Karle et al., “Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine,” Cancer Gene Therapy, vol. 7, no. 4, pp. 629–636, 2000. View at Publisher · View at Google Scholar
  24. B. Salmons, M. Löhr, and W. H. Günzburg, “Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial,” Journal of Gastroenterology, vol. 38, 15, pp. 78–84, 2003. View at Google Scholar
  25. M. Löhr, A. Hoffmeyer, J.-C. Kröger et al., “Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma,” The Lancet, vol. 357, no. 9268, pp. 1591–1592, 2001. View at Publisher · View at Google Scholar
  26. J. Hlavaty, A. Stracke, D. Klein, B. Salmons, W. H. Günzburg, and M. Renner, “Multiple modifications allow high-titer production of retroviral vectors carrying heterologous regulatory element,” Journal of Virology, vol. 78, no. 3, pp. 1384–1392, 2004. View at Publisher · View at Google Scholar
  27. R. Klein, B. Ruttkowski, E. Knapp, B. Salmons, W. H. Günzburg, and C. Hohenadl, “WPRE-mediated enhancement of gene expression is promoter and cell line specific,” Gene, vol. 372, pp. 153–161, 2006. View at Publisher · View at Google Scholar
  28. K. Pambalk, C. Hohenadl, B. Salmons, W. H. Günzburg, and M. Renner, “Specific packaging of spliced retroviral vector transcripts lacking the ψ-region,” Biochemical and Biophysical Research Communications, vol. 293, no. 1, pp. 239–246, 2002. View at Publisher · View at Google Scholar
  29. F. L. Graham, J. Smiley, W. C. Russell, and R. Nairn, “Characteristics of a human cell line transformed by DNA from human adenovirus type 5,” Journal of General Virology, vol. 36, no. 1, pp. 59–72, 1977. View at Google Scholar
  30. R. A. Crandell, C. G. Fabricant, and W. A. Nelson-Rees, “Development, characterization, and viral susceptibility of a feline (Felis catus) renal cell line (CRFK),” In Vitro, vol. 9, no. 3, pp. 176–185, 1973. View at Publisher · View at Google Scholar
  31. I. Keydar, L. Chen, S. Karby et al., “Establishment and characterization of a cell line of human breast carcinoma origin,” European Journal of Cancer & Clinical Oncology, vol. 15, no. 5, pp. 659–670, 1979. View at Google Scholar
  32. W. H. Günzburg, P. Karle, R. Renz, B. Salmons, and M. Renner, “Characterization of a human cell clone expressing cytochrome P450 for safe use in human somatic cell therapy,” Annals of the New York Academy of Sciences, vol. 880, pp. 326–336, 1999. View at Publisher · View at Google Scholar
  33. L. Chen, D. J. Waxman, D. Chen, and D. W. Kufe, “Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene,” Cancer Research, vol. 56, no. 6, pp. 1331–1340, 1996. View at Google Scholar
  34. P. S. Gaynon and A. L. Carrel, “Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia,” Advances in Experimental Medicine and Biology, vol. 457, pp. 593–605, 1999. View at Google Scholar
  35. S. Greenstein, K. Ghias, N. L. Krett, and S. T. Rosen, “Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies,” Clinical Cancer Research, vol. 8, no. 6, pp. 1681–1694, 2002. View at Google Scholar
  36. R. Sharma, P. Tobin, and S. J. Clarke, “Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea,” The Lancet Oncology, vol. 6, no. 2, pp. 93–102, 2005. View at Publisher · View at Google Scholar
  37. K. Jordan, C. Kasper, and H.-J. Schmoll, “Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment,” European Journal of Cancer, vol. 41, no. 2, pp. 199–205, 2005. View at Publisher · View at Google Scholar
  38. J. E. Wright, O. Tretyakov, L. J. Ayash, A. Elias, A. Rosowsky, and E. Frei, “Analysis of 4-hydroxycyclophosphamide in human blood,” Analytical Biochemistry, vol. 224, no. 1, pp. 154–158, 1995. View at Publisher · View at Google Scholar